Publications
5803 Results
- Journal / Conference
- Clinical Trials 2(Suppl 1):S81 (#P80)
- Year
- 2005
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000
Minority participant accrual workshops-innovative strategy to increase African American accrual
- Journal / Conference
- Clinical Trials 2(Suppl 1):S24 (#05)
- Year
- 2005
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000
The black church: an invaluable ally for enhancing minority recruitment
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):623s (#7008)
- Year
- 2005
- Research Committee(s)
- Lung
- Study Number(s)
- S0126
Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib
- Journal / Conference
- Journal of Cancer Education 20(3) Suppl:15 (#13)
- Year
- 2005
The Southwest Oncology Group (SWOG) young investigators training program (YITP), a practical experience
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):624s (#7014)
- Year
- 2005
- Research Committee(s)
- Lung
- Study Number(s)
- SWOG-9336
Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American intergroup 0139 (RTOG 9309)
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):634s (#7058)
- Year
- 2005
- Research Committee(s)
- Lung
- Study Number(s)
- S0023
Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):21s (#572)
- Year
- 2005
- Research Committee(s)
- Breast
- Study Number(s)
- S9623
SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (ACHPCS) for primary breast cancer in women with >4 involved axillary lymph nodes.
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):385s (#4531)
- Year
- 2005
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)
Optimal combined modality treatment improves outcome of locally advanced bladder cancer: analyis of SWOG 8710
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):33s (#620)
- Year
- 2005
- Research Committee(s)
- Breast
- Study Number(s)
- C9741
Dose-dense (DD)AC followed by paclitaxel is associated with moderate frequent anemia compared to sequential (S) and/or less DD Treatment: update by CALGB on breast cancer intergroup trial C9741 with ECOG, SWOG, & NCCTG
- Journal / Conference
- Journal of the National Cancer Institute 97(17):1262-1271
- Year
- 2005
- Research Committee(s)
- Breast
- Study Number(s)
- JMA17